Healthcare Analytical Testing Services Market worth $12,470 million by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global healthcare analytical testing services market will grow from $7.75B in 2026 to $12.47B by 2031, representing a 10% CAGR. Growth is attributed to pharmaceutical and biopharmaceutical outsourcing, tighter regulatory requirements, biologics and cell-and-gene-therapy development, and laboratory infrastructure investment. Bioanalytical testing represented the largest service segment at 37%, while North America held 45% of the market; Asia-Pacific is forecast to post the fastest growth. Eurofins, Labcorp and other major providers are expanding capabilities through acquisitions, specialized testing services, automation and AI-enabled workflows.

Analysis

This is a low-information, vendor-sponsored TAM estimate rather than a new demand datapoint; it should not move broad CRO valuations. The investable implication is narrower: regulated testing has unusually sticky revenue because switching laboratories requires method-transfer work, comparability studies, and renewed validation. That creates pricing durability for scaled networks such as Eurofins (ERF), Intertek (ITRK) and SGS (SGSN), while smaller specialist labs face rising compliance and automation capex that can force consolidation.

The key differentiation is mix, not headline growth. ERF and ITRK have more direct exposure to recurring release, stability and compliance testing; ICLR and IQV monetize testing largely as part of broader development programs, so their earnings sensitivity is more tied to biopharma funding and trial starts. CRL has potential upside from complex biologics analytics but remains exposed to utilization and fixed-cost absorption across its wider discovery platform; a modest testing tailwind will not offset a weak order environment.

Over 1-3 months, the relevant catalysts are bookings, organic-growth commentary, laboratory utilization and price/mix disclosures—not another market forecast. Over 6-18 months, advanced-therapy pipelines could lift revenue per sample and increase barriers to entry, but automation is two-sided: it expands throughput at leaders while ultimately pressuring unit pricing in standardized assays. Consensus may over-credit AI as immediate margin expansion; validation requirements mean labor savings will likely be reinvested into capacity and turnaround-time competition before reaching EBIT.

A more actionable second-order angle is M&A: fragmented regional labs with oncology, pathology, or cell-and-gene analytical capabilities are strategic bolt-ons for LH and ERF. Acquisitions can be accretive only if acquired testing volume is routed through existing lab networks; bidding for scarce specialty assets risks converting a favorable structural growth narrative into goodwill and integration risk.

Key Decisions for Investors

• Maintain/establish a 6-12 month long ERF versus short CRL pair, sized market-neutral: ERF offers more direct recurring compliance-testing exposure, while CRL needs broader discovery demand recovery. Reassess if CRL reports two consecutive quarters of improving book-to-bill and margin recovery, or if ERF organic laboratory growth decelerates below mid-single digits.
• Add ITRK or SGSN on post-results weakness only if management confirms price/mix-led organic growth and stable laboratory utilization; target a 12-month 10-15% total-return profile rather than a near-term catalyst trade. Exit on evidence that automation-driven price concessions exceed productivity gains.
• Do not chase LH solely on this theme. Use LH earnings as an alert: a material increase in specialty-testing revenue and margin guidance would support a tactical 3-6 month long; absent segment disclosure, the analytical-testing contribution is too diluted to underwrite.
• Monitor specialty-lab M&A valuations and announced transactions for ERF/LH. Favor acquirers only where disclosed synergies imply network consolidation; avoid adding after deals priced at premium multiples without a credible route-to-lab utilization benefit.